-
Mashup Score: 6
Sia Daneshmand, MD, and Karine Tawagi, MD, join Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for non–muscle-invasive bladder cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1ICI Outcomes Better in PD-L1-Positive Metastatic Urothelial Carcinoma - Renal and Urology News - 15 day(s) ago
Investigators report findings from a systematic review and meta-analysis of 14 studies.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Enfortumab Vedotin Maintains HRQoL in Pretreated Advanced Urothelial Carcinoma - Renal and Urology News - 16 day(s) ago
Patients treated with enfortumab vedotin vs chemotherapy reported greater pain reduction but worse appetite loss.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 3
Alex Chehrazi-Raffle, MD, discussed a real-world analysis of clinical characteristics of patients with bladder cancer receiving adjuvant nivolumab or chemotherapy.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Systemic Therapy Alone Linked to Worse Survival in Advanced Bladder Cancer - Renal and Urology News - 30 day(s) ago
More extensive lymph node dissection was significantly associated with better survival.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Enfortumab Vedotin/Pembrolizumab Signals Shift in Urothelial Carcinoma Treatment Paradigm - 1 month(s) ago
Matthew Galsky, MD, discusses the significance of the FDA approval of enfortumab vedotin plus pembrolizumab as a first-line regimen in urothelial cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Understanding Adjuvant Therapy for Upper Tract Urothelial Carcinoma - 1 month(s) ago
Published online: February 15, 2024 Request permissions for this article. Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY Matthew D. Galsky, MD, Division of Hematology and Medical Oncology, Department of Medicine, 1470 Madison Ave, New York, NY 10029; e-mail: [email protected]. Understanding Adjuvant Therapy for Upper Tract Urothelial Carcinoma. JCO 0, JCO.23.02679
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Enfortumab Vedotin/Pembrolizumab Signals Shift in Urothelial Carcinoma Treatment Paradigm - 1 month(s) ago
Matthew Galsky, MD, discusses the significance of the FDA approval of enfortumab vedotin plus pembrolizumab as a first-line regimen in urothelial cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Data from the phase 3 EV-302 trial support the supplemental biologics license application for enfortumab vedotin plus pembrolizumab for patients with advanced or metastatic urothelial cancer in Japan.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
Sia Daneshmand, MD, and Karine Tawagi, MD, join Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for non–muscle-invasive bladder cancer. #blcsm | @OncBrothers @siadaneshmand @DrKarineTawagi https://t.co/wl66pY5FtG